Clin2
NCT07553637Possibly a fitRecruiting

ALTO-207 for Adults With Hard-to-Treat Depression

Treatment-resistant Depression (TRD)

Part of Mental health clinical trials.

This study tests whether a new medication called ALTO-207 can help people with depression that hasn't improved with standard antidepressants. You may qualify if you've tried multiple antidepressants without enough relief and are willing to add this experimental treatment to your current medication.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
178 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • Age 18–75 years old
  • Diagnosed with moderate-to-severe depression (major depressive disorder) without hallucinations or delusions
  • Tried at least 2–5 antidepressants in the past with less than 50% improvement
  • Currently taking 1–2 antidepressant medications at a stable dose
  • No bipolar disorder, psychotic disorder, or significant untreated trauma symptoms
  • No severe medical conditions or recent participation in other psychiatric drug trials

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07080723Recruiting· Phase 4
Guided treatment vs usual care for stubborn depression

This trial tests if using an algorithm to guide treatment works better than standard care for people whose depression hasn't gotten better with previous treatments. It aims to find a more effective approach for those with treatment-resistant depression.

Aalborg
NCT07210112Not yet recruiting· Phase 2
Psilocybin and Trazodone for tough-to-treat depression

This trial tests if taking psilocybin (a psychedelic drug) with trazodone (an antidepressant) can help people whose depression hasn't improved with at least two standard antidepressants. If you have treatment-resistant depression, this study might be an option.

Paris
NCT07284667Recruiting· Phase 2
A new medicine for depression that hasn't improved with other treatments

This trial tests a new medicine called ACP-211 in adults with major depression who have not gotten enough relief from at least two previous antidepressants. The goal is to see if it can help when other treatments have not worked well.

Birmingham, Alabama
NCT06633016Recruiting· Phase 2
ABX-002 for major depression (add-on treatment)

This trial tests a new medication called ABX-002 as an add-on to your current antidepressant. It's for people with moderate to severe depression who haven't gotten enough help from their current antidepressant alone.

Birmingham, Alabama
NCT05922878Recruiting· Phase 2
ALTO-300 study for moderate to severe depression

This trial tests ALTO-300 as an add-on treatment for people with moderate to severe major depressive disorder (MDD). It aims to see whether ALTO-300 helps improve depression symptoms when you’re already on a stable antidepressant.

Phoenix, Arizona
NCT06656416Recruiting· Phase 2
ALTO-100 for bipolar depression

This trial tests an investigational drug called ALTO-100 in people with bipolar I or II who are currently experiencing depression. It looks at whether this new medicine can help improve depression symptoms when taken alongside your usual mood stabilizer or antipsychotic medication.

Chandler, Arizona

Hear when a new Treatment-resistant Depression (TRD) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.